miR-106b as an emerging therapeutic target in cancer

Surendra Kumar Sagar

doi:10.1016/j.gendis.2021.02.002

您当前的位置：

首页 >

文章列表页 >

miR-106b as an emerging therapeutic target in cancer

更新时间：2022-06-24

- miR-106b as an emerging therapeutic target in cancer
- Genes & Diseases Vol. 9, Issue 4, (2022)
- 作者机构：
  
  Department of Zoology, Swami Shraddhanand College, University of Delhi, Delhi,India,110036
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.02.002
  CLC：
- Published：2022，
  
  Published Online：1 July 2022，
扫描看全文
Surendra Kumar Sagar. miR-106b as an emerging therapeutic target in cancer. [J]. Genes & Diseases 9(4).(2022)
DOI：

Surendra Kumar Sagar. miR-106b as an emerging therapeutic target in cancer. [J]. Genes & Diseases 9(4).(2022) DOI： 10.1016/j.gendis.2021.02.002.

摘要

Abstract

MicroRNAs (miRNAs) comprise short non-coding RNAs that function in regulating the expression of tumor suppressors or oncogenes and modulate oncogenic signaling pathways in cancer. miRNAs expression alters significantly in several tumor tissues and cancer cell lines. For example

miR-106b functions as an oncogene and increases in multiple cancers. The miR-106b directly targets genes involved in tumorigenesis

proliferation

invasion

migration

and metastases. This review has focused on the miR-106b function and its downstream target in different cancers and provide perspective into how miR-106 regulates cancer cell proliferation

migration

invasion

and metastases by regulating the tumor suppressor genes. Since miRNAs-based therapies are currently being developed to enhance cancer therapy outcomes

miR-106b could be an attractive and prospective candidate in different cancer types for detection

diagnosis

and prognosis assessment in the tumor.

关键词

Keywords

ApoptosisCancerMetastasesmiRNAOncogeneTumor suppressor

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

MicroRNA-9 as a paradoxical but critical regulator of cancer metastasis: Implications in personalized medicine

Autophagy-related lncRNAs in tumor progression and drug resistance: A double-edged sword

DEAD-box RNA helicases with special reference to p68: Unwinding their biology, versatility, and therapeutic opportunity in cancer

A novel aptamer-based small RNA delivery platform and its application to cancer therapy

Chaperone-assisted E3 ligase CHIP: A double agent in cancer

Related Author

Yichen Liu

Qiong Zhao

Tao Xi

Lufeng Zheng

Xiaoman Li

Yunchao Zhang

Jiayu Tang

Cheng Wang

Related Institution

Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine

School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 639 Longmian Road

School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine

School of Pharmacy, Chengdu University of Traditional Chinese Medicine

Institute of Translational Pharmacology and Clinical Application, Sichuan Academy of Chinese Medical Science

⁰